Other weight-loss drugs are currently in development or regulatory approval stages, including: Once-daily GLP-1 pill orforglipron (Eli Lilly), which, when taken alongside a healthy diet and exercise, resulted in a 7.5% weight loss over 72 weeks on the 6mg dose, 8.4% loss with 12mg of orforglipron, and 11.2% loss with 36mg of orforglipron, as compared with 2.1% loss with placebo (funded by Eli Lilly
Both peptides trigger this release through the growth hormone secretagogue receptor (GHS-R) not the normal growth hormone-releasing hormone (GHRH) pathway
Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific
Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, et al